A Phase 1 interventional study of axitinib and crizotinib in Advanced Solid Tumors, sponsored by Pfizer. Completed at 17 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-24.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Carcinoma by Pfizer — 6 open to participants now, 6 under way, 2 of them phase 3. Carcinoma · Pfizer.
Among the 27 studies in Carcinoma by Pfizer, this one is the 18th largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2014, is one of 9 in phase 1, and was the 19th registered.
736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.
Browse Carcinoma studies →6 of the 27 studies in Carcinoma by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Australia, China and 8 more countries
Ages 18+
Pfizer · Sites in United States, Australia, China and 3 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, Australia and 28 more countries
Ages 18+
By country, each count listing its studies:
Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 10 · Phase 3 3 · Phase 4 2
First in 2001; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is close to the median of 49 across 571 interventional studies indexed under Carcinoma.
Median enrollment 98 across the 24 interventional studies, 684 across the 3 observational. Of the 21 that completed or were terminated, 12 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
1 of the studies in Carcinoma by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07227415PfizerSymbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer | 2027-11-02 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies in Carcinoma by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Despite the success of anti-angiogenic therapy in multiple treatment settings, a fraction of patients are refractory to vascular endothelial growth factor (VEGF) inhibitor treatment, while the majority of patients will eventually develop evasive resistance. It is proposed that mesenchymal-epithelial transition factor (c-MET) and its ligand hepatocyte growth factor (HGF or scatter factor) contribute to VEGF inhibitor resistance, such that combining a c-MET inhibitor with a VEGF inhibitor will provide additional clinical activity compared to VEGF inhibitor alone. This hypothesis will be tested using the cMET/ALK inhibitor, crizotinib, in combination with the VEGF inhibitor, axitinib.Since this will be the first study of axitinib given in combination with crizotinib, the study will primarily assess the safety and tolerability of the combination regimen.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose Escalation Advanced solid tumor that is resistant to standard therapy or for which no standard therapy is available
Drug: axitinib · Drug: crizotinib
Dose Expansion, Cohort 1: axitinib in combination with crizotinib Advanced renal cell cancer \[RCC\] with no prior systemic therapy
Drug: axitinib · Drug: crizotinib
Dose Expansion, Cohort 2: axitinib in combination with crizotinib Advanced renal cell cancer with at least one but no more than two prior systemic treatment regimens directed at advanced RCC
Drug: axitinib · Drug: crizotinib
Axitinib: tablets, dosage range 2 - 5 mg, given orally twice daily on a continuous dosing schedule in 28 days cycles.
Crizotinib: capsules, dosage range 200-250 mg, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
Axitinib: tablets, dosage be defined based on Arm 1 results, given orally twice daily on a continuous dosing schedule in 28 days cycles.
Crizotinib: capsules, dosage be defined based on Arm 1 results, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
Axitinib: tablets, dosage be defined based on Arm 1 results, given orally twice daily on a continuous dosing schedule in 28 days cycles.
Crizotinib: capsules, dosage be defined based on Arm 1 results, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
Dose-Escalation Part: Number of Participants With Dose-Limiting Toxicities (DLTs)
Toxicity as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03. DLT defined as any following events attributable to any (axitinib or crizotinib) or both agents in combination: hematologic (Grade 4 neutropenia, absolute neutrophil count\<1000/mm\^3 with single temperature of \>38.3 degrees celsius or sustained temperature of 38 degrees celsius for \>1 hour; \>=Grade 3 neutropenic infection; \>=Grade 3 thrombocytopenia with bleeding; Grade 4 thrombocytopenia), non-hematologic (\>=Grade 3 toxicities \[except asymptomatic hypophosphatemia, hyperuricemia without signs, symptoms of gout, and tumor lysis syndrome\], nausea, vomiting or diarrhea persisted at Grade 3 or 4 despite maximal medical therapy; Grade 3 hypertension if persistent despite anti-hypertensives); In asymptomatic participant, Grade 3 QTc prolongation (QTc\>=501 msec) if persisted after correcting reversible causes, and failure to deliver \>=75 percent (%) of dose of each study drug.
Time frame: Cycle 1 (28 days)
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drugs (crizotinib and axitinib) without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and until 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.
Time frame: First dose of study drug until 28 days after last dose (up to 35 cycles in Part 1 and 35 cycles in Part 2, each cycle 28 days)
Number of Participants With Treatment-Related Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Treatment-related AE was any untoward medical occurrence attributed to study drugs (crizotinib and axitinib) in a participant who received study drugs. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and until 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.
Time frame: First dose of study drug until 28 days after last dose (up to 35 cycles in Part 1 and 35 cycles in Part 2, each cycle 28 days)
Number of Participants With Grade 3 or Higher Adverse Events (AEs) as Graded by National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 4.03
An AE was any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Grade 3 (severe) events=unacceptable or intolerable events, significantly interrupting usual daily activity, require systemic drug therapy/other treatment. Grade 4 (Life-threatening) events caused participant to be in imminent danger of death. Grade 5 = death. Treatment-emergent were events between first dose of study drug and until 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.
Time frame: First dose of study drug until 28 days after last dose (up to 35 cycles in Part 1 and 35 cycles in Part 2, each cycle 28 days)
Number of Participants With Clinically Significant Laboratory Abnormalities Based on National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 4.03: Hematological Test Abnormalities
Laboratory parameters included hematological and biochemistry parameters. Hematological parameters included haemoglobin (anemia, haemoglobin increased), lymphocytes (lymphopenia, lymphocyte count increased), neutrophils, platelets and white blood cells. Number of participants with hematological abnormalities by grades (as per NCI CTCAE version 4.03) were reported. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.
Time frame: Baseline up to end of treatment (up to 35 cycles in Part 1 and 35 cycles in Part 2, each cycle 28 days)
Number of Participants With Clinically Significant Laboratory Abnormalities Based on National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 4.03: Biochemistry Test Abnormalities
Laboratory parameters included hematological and biochemistry parameters. Biochemistry parameters/abnormalities included alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin (total), creatinine, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia and gamma glutamyl transferase Number of participants with biochemistry test abnormalities by grades (NCI CTCAE version 4.03) were reported. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.
Time frame: Baseline up to end of treatment (up to 35 cycles in Part 1 and 35 cycles in Part 2, each cycle 28 days)
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Day 1, 15 of Cycle 1, Day 1 of Cycles 2, 4, 6, 12, 24 and End of Treatment Visit
Time frame: Baseline; Day 1 and 15 of Cycle 1; Day 1 of Cycles 2, 4, 6, 12, 24; and end of treatment (up to a maximum duration of 35 cycles in Part 1 and 35 cycles in Part 2, each cycle 28 days)
Change From Baseline in Pulse Rate at Day 1, 15 of Cycle 1, Day 1 of Cycles 2, 4, 6, 12, 24 and End of Treatment
Time frame: Baseline; Day 1 and 15 of Cycle 1; Day 1 of Cycles 2, 4, 6, 12, 24; and end of treatment (any time up to a maximum duration of 35 cycles in Part 1 and 35 cycles in Part 2, each cycle 28 days)
Change From Baseline in Body Weight at Day 1, 15 of Cycle 1, Day 1 of Cycles 2, 4, 6, 12, 24 and End of Treatment
Time frame: Baseline; Day 1 and 15 of Cycle 1; Day 1 of Cycles 2, 4, 6, 12, 24; and end of treatment (any time up to a maximum duration of 35 cycles in Part 1 and 35 cycles in Part 2, each cycle 28 days)
Number of Participants With Change From Baseline in Eastern Cooperative Oncology Group Performance Status (ECOG-PS) to Worst Value
ECOG-PS: used to assess how disease affected the daily living abilities of participant. It ranges on the scale from: 0-5 (0=fully active/able to carry on all pre-disease activities without restriction;1=restricted in physically strenuous activity but ambulatory/able to carry out light/sedentary work;2=ambulatory \[for more than (\>)50%of waking hours\], capable of all self-care but unable to carry out any work activities;3=capable of limited self-care, confined to bed or chair \[for \>50% of waking hours\];4=completely disabled, not capable of any self-care, totally confined to bed or chair;5= dead, higher score=more functional impairment) and changes to worst status scores were presented. Baseline value=value collected prior to first dose of study drug on Cycle 1 Day 1. Worst post-baseline value=worst value between first dose of any study drug and end of treatment (EOT) visit. Shift to low refers to lower than Baseline value; shift to high refers to higher than baseline value for ECOG-PS.
Time frame: Baseline, End of Treatment (up to Cycle 35 [for Part 1] and up to Cycle 35 [for Part 2], each cycle 28 days)
Number of Participants With Maximum Increase From Baseline in QTc Interval
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Number of participants with maximum increase from baseline of less than (\<) 30 milliseconds (msec), 30 to \<60 msec and greater than or equal to (\>=) 60 msec were reported.
Time frame: Baseline, End of Treatment (up to Cycle 35 [for Part 1] and up to Cycle 35 [for Part 2], each cycle 28 days)
Maximum Observed Plasma Concentration (Cmax) of Axitinib and Crizotinib
Data of this outcome measure was not planned to be analyzed for Cohort 2 in dose expansion part, as pre-specified in protocol.
Time frame: Axitinib: Pre-dose (0 hour [hr]), 1, 2, 3, 4, 6, 8 hrs post-dose at Lead-in Day 7, Cycle 1 Day 15; Crizotinib: pre-dose (0 hr), 1, 2, 3, 4, 6, 8 hrs post-dose at Cycle 1 Day 15
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Axitinib and Crizotinib
Data of this outcome measure was not planned to be analyzed for Cohort 2 in dose expansion part, as pre-specified in protocol.
Time frame: Axitinib: Pre-dose (0 hour [hr]), 1, 2, 3, 4, 6, 8 hrs post-dose at Lead-in Day 7, Cycle 1 Day 15; Crizotinib: pre-dose (0 hr), 1, 2, 3, 4, 6, 8 hrs post-dose at Cycle 1 Day 15
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Axitinib and Crizotinib
Area under the plasma concentration versus time-curve from time zero to end of dosing interval (AUCtau), where dosing interval was 12 hours. Data of this outcome measure was not planned to be analyzed for Cohort 2 in dose expansion part, as pre-specified in protocol.
Time frame: Axitinib: Pre-dose (0 hour [hr]), 1, 2, 3, 4, 6, 8 hrs post-dose at Lead-in Day 7, Cycle 1 Day 15; Crizotinib: pre-dose (0 hr), 1, 2, 3, 4, 6, 8 hrs post-dose at Cycle 1 Day 15
Apparent Oral Clearance (CL/F) of Axitinib and Crizotinib
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent oral clearance was obtained by dividing study drug dose with AUCtau, where AUCtau was area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval. Data of this outcome measure was not planned to be analyzed for Cohort 2 in dose expansion part, as pre-specified in protocol.
Time frame: Axitinib: Pre-dose (0 hour [hr]), 1, 2, 3, 4, 6, 8 hrs post-dose at Lead-in Day 7, Cycle 1 Day 15; Crizotinib: pre-dose (0 hr), 1, 2, 3, 4, 6, 8 hrs post-dose at Cycle 1 Day 15
Apparent Volume of Distribution (Vz/F) of Axitinib and Crizotinib
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
Time frame: Axitinib: Pre-dose (0 hour [hr]), 1, 2, 3, 4, 6, 8 hrs post-dose at Lead-in Day 7, Cycle 1 Day 15; Crizotinib: pre-dose (0 hr), 1, 2, 3, 4, 6, 8 hrs post-dose at Cycle 1 Day 15
Percentage of Participants With Objective Response
Percentage of participants with objective response based on assessment of confirmed complete response \[CR\] or confirmed partial response \[PR\] according to Response Evaluation Criteria In Solid Tumors \[RECIST\] version1.1 were reported. Confirmed responses were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.
Time frame: From Baseline until disease progression or death, whichever occurred first (up to 35 cycles in Part 1 and 35 cycles in Part 2, each cycle 28 days)
Dose Expansion Part: Duration of Response
Duration of response (as per Response Evaluation Criteria in Solid Tumors \[RECIST\] version 1.1) was defined as the time (in months) from first documentation of objective tumor response (complete response \[CR\] or partial response \[PR\]) until the first date that recurrent, progressive disease, or death (whichever occurred first). CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent. Progression was defined as \>= 20 percent increase in sum of longest diameter of target lesions; measurable increase in non-target lesion; appearance of new lesions.
Time frame: From first objective response until first recurrent, disease progression, or death, whichever occurred first (up to 35 cycles, each cycle 28 days)
Dose Expansion Part: Progression-Free Survival (PFS)
PFS (as per Response Evaluation Criteria in Solid Tumors \[RECIST\] version 1.1) was defined as the time (in months) from start of study treatment to first documentation of objective tumor progression or death due to any cause, whichever occurred first. PFS (in months) was calculated as (first event date minus date of first dose of study medication plus 1) divided by 30.44. Progression was defined as \>= 20 percent increase in sum of longest diameter of target lesions; measurable increase in non-target lesion; appearance of new lesions. PFS was not estimated in Dose Expansion Cohort 2 due to small sample size.
Time frame: From Baseline until disease progression or death, whichever occurred first (up to 35 cycles, each cycle 28 days)
Dose Expansion Part Cohort 1: Levels of Serum Soluble Protein Biomarkers
Serum soluble protein biomarkers included angiopoietin-2, Hepatocyte Growth Factor (HGF), Vascular Endothelial Growth Factor Receptor 3 (VEGFR 3). Biomarker analysis was not planned to be performed in dose escalation part and Cohort 2 of dose expansion part, as pre-specified in protocol.
Time frame: Baseline, Cycle 2 Day 1, end of treatment (up to 35 cycles, each cycle 28 days)
Dose Expansion Part Cohort 1: Change From Baseline in Serum Concentration of Circulating microRNAs (miRNA) at End of Treatment
Time frame: Baseline, end of treatment (up to 35 cycles, each cycle 28 days)
Dose Expansion Part Cohort 1: Percentage of c-MET Positive Tumor Cell at Baseline in Relation to Objective Response Rate (ORR)
Percentage of c-MET positive tumor cell for objective response (complete response \[CR\] + partial response \[PR\]) is reported. Objective response was defined as CR and PR. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent. Biomarker analysis was not planned to be performed in dose escalation part and Cohort 2 of dose expansion part, as pre-specified in protocol.
Time frame: Baseline
Dose Expansion Part Cohort 1: Level of Plasma Soluble Protein Biomarker (c-MET)
Plasma soluble protein biomarker included c-MET. Biomarker analysis was not planned to be performed in dose escalation part and Cohort 2 of dose expansion part, as pre-specified in protocol.
Time frame: Baseline; Day 1 and 15 of Cycle 1; Day 1 of Cycles 2, 3, 5; end of treatment (up to 35 cycles, each cycle 28 days)
Dose Expansion Part Cohort 1: Ratio of Serum Soluble Protein Biomarkers Level to Baseline Biomarkers Level by Each Timepoint
Serum soluble protein biomarkers included angiopoietin-2, Hepatocyte Growth Factor (HGF), Vascular Endothelial Growth Factor Receptor 3 (VEGFR3). Ratio=value of serum soluble protein biomarkers at each time point to the value at baseline. Biomarker analysis was not planned to be performed in dose escalation part and Cohort 2 of dose expansion part, as pre-specified in protocol.
Time frame: Baseline, Cycle 2 Day 1, end of treatment (up to 35 cycles, each cycle 28 days)
This study was conducted in 2 parts: Part 1 (Dose escalation part to determine maximum tolerated dose \[MTD\] of axitinib in combination with crizotinib), Part 2 (Dose expansion part to assess the safety and tolerability of axitinib in combination with crizotinib at MTD determined in Part 1).
| Milestone | Dose Escalation Part: Crizotinib 200mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 250mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 200 mg+Axitinib 5 mg | Dose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg |
|---|---|---|---|---|---|---|
| Started | 5 | 3 | 5 | 11 | 0 | 0 |
| Treated | 5 | 3 | 4 | 10 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 5 | 3 | 5 | 11 | 0 | 0 |
| Withdrew: Participant refused further follow-up | 1 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Enrolled but not treated | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Disease progression | 3 | 2 | 3 | 6 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Global deterioration of health status | 1 | 0 | 0 | 1 | 0 | 0 |
| Milestone | Dose Escalation Part: Crizotinib 200mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 250mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 200 mg+Axitinib 5 mg | Dose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 21 | 7 |
| Treated | 0 | 0 | 0 | 0 | 21 | 7 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 21 | 7 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 2 | 1 |
| Withdrew: Disease progression | 0 | 0 | 0 | 0 | 9 | 3 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 4 | 2 |
| Withdrew: Participant's non-compliance | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Participant refused further follow-up | 0 | 0 | 0 | 0 | 4 | 0 |
| Withdrew: Changed to standard of care | 0 | 0 | 0 | 0 | 1 | 0 |
Toxicity as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03. DLT defined as any following events attributable to any (axitinib or crizotinib) or both agents in combination: hematologic (Grade 4 neutropenia, absolute neutrophil count\<1000/mm\^3 with single temperature of \>38.3 degrees celsius or sustained temperature of 38 degrees celsius for \>1 hour; \>=Grade 3 neutropenic infection; \>=Grade 3 thrombocytopenia with bleeding; Grade 4 thrombocytopenia), non-hematologic (\>=Grade 3 toxicities \[except asymptomatic hypophosphatemia, hyperuricemia without signs, symptoms of gout, and tumor lysis syndrome\], nausea, vomiting or diarrhea persisted at Grade 3 or 4 despite maximal medical therapy; Grade 3 hypertension if persistent despite anti-hypertensives); In asymptomatic participant, Grade 3 QTc prolongation (QTc\>=501 msec) if persisted after correcting reversible causes, and failure to deliver \>=75 percent (%) of dose of each study drug.
| Participants | Dose Escalation Part: Crizotinib 200mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 250mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 200 mg+Axitinib 5 mg | Dose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg |
|---|---|---|---|---|
| Dose-Escalation Part: Number of Participants With Dose-Limiting Toxicities (DLTs) | 0 | 0 | 0 | 0 |
An AE was any untoward medical occurrence in a participant who received study drugs (crizotinib and axitinib) without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and until 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.
| Participants | Dose Escalation Part: Crizotinib 200mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 250mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 200 mg+Axitinib 5 mg | Dose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg |
|---|---|---|---|---|---|---|
| AEs | 5 | 3 | 3 | 10 | 21 | 7 |
| SAEs | 2 | 2 | 0 | 5 | 8 | 3 |
Treatment-related AE was any untoward medical occurrence attributed to study drugs (crizotinib and axitinib) in a participant who received study drugs. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and until 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.
| Participants | Dose Escalation Part: Crizotinib 200mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 250mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 200 mg+Axitinib 5 mg | Dose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg |
|---|---|---|---|---|---|---|
| AEs | 4 | 3 | 3 | 9 | 21 | 6 |
| SAEs | 1 | 0 | 0 | 2 | 1 | 2 |
An AE was any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Grade 3 (severe) events=unacceptable or intolerable events, significantly interrupting usual daily activity, require systemic drug therapy/other treatment. Grade 4 (Life-threatening) events caused participant to be in imminent danger of death. Grade 5 = death. Treatment-emergent were events between first dose of study drug and until 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.
| Participants | Dose Escalation Part: Crizotinib 200mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 250mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 200 mg+Axitinib 5 mg | Dose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg |
|---|---|---|---|---|---|---|
| Grade 3 or 4 AEs | 3 | 3 | 1 | 8 | 19 | 6 |
| Grade 5 AEs | 0 | 1 | 0 | 0 | 2 | 0 |
Laboratory parameters included hematological and biochemistry parameters. Hematological parameters included haemoglobin (anemia, haemoglobin increased), lymphocytes (lymphopenia, lymphocyte count increased), neutrophils, platelets and white blood cells. Number of participants with hematological abnormalities by grades (as per NCI CTCAE version 4.03) were reported. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.
| Participants | Dose Escalation Part: Crizotinib 200mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 250mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 200 mg+Axitinib 5 mg | Dose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg |
|---|---|---|---|---|---|---|
| Anemia: Grade 1 | 1 | 1 | 0 | 2 | 10 | 3 |
| Anemia: Grade 2 | 0 | 0 | 0 | 1 | 2 | 2 |
| Anemia: Grade 3 | 0 | 0 | 0 | 0 | 1 | 0 |
| Anemia: Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased: Grade 1 | 0 | 1 | 0 | 1 | 1 | 0 |
| Hemoglobin increased: Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased: Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphopenia: Grade 1 | 1 | 0 | 0 | 1 | 0 | 0 |
| Lymphopenia: Grade 2 | 0 | 0 | 1 | 2 | 7 | 4 |
| Lymphopenia: Grade 3 | 1 | 0 | 0 | 2 | 2 | 0 |
| Lymphopenia: Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils (absolute): Grade 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Neutrophils (absolute): Grade 2 | 0 | 0 | 0 | 0 | 0 | 1 |
| Neutrophils (absolute): Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils (absolute): : Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets: Grade 1 | 0 | 1 | 1 | 2 | 6 | 2 |
| Platelets: Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets: Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| White blood cells: Grade 1 | 1 | 0 | 1 | 0 | 6 | 1 |
| White blood cells: Grade 2 | 0 | 0 | 0 | 0 | 1 | 1 |
| White blood cells: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| White blood cells: Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased: Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased: Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased: Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
Laboratory parameters included hematological and biochemistry parameters. Biochemistry parameters/abnormalities included alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin (total), creatinine, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia and gamma glutamyl transferase Number of participants with biochemistry test abnormalities by grades (NCI CTCAE version 4.03) were reported. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.
| Participants | Dose Escalation Part: Crizotinib 200mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 250mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 200 mg+Axitinib 5 mg | Dose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg |
|---|---|---|---|---|---|---|
| Alanine aminotransferase: Grade 1 | 1 | 1 | 2 | 3 | 6 | 1 |
| Alanine aminotransferase: Grade 2 | 0 | 0 | 1 | 1 | 3 | 0 |
| Alanine aminotransferase: Grade 3 | 0 | 1 | 0 | 1 | 2 | 0 |
| Alanine aminotransferase: Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase: Grade 1 | 1 | 1 | 3 | 6 | 9 | 0 |
| Alkaline phosphatase: Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase: Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase: Grade 1 | 1 | 1 | 3 | 3 | 7 | 2 |
| Aspartate aminotransferase: Grade 2 | 0 | 0 | 0 | 2 | 3 | 0 |
| Aspartate aminotransferase: Grade 3 | 0 | 0 | 0 | 0 | 1 | 0 |
| Aspartate aminotransferase: Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bilirubin (total): Grade 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Bilirubin (total): Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bilirubin (total): Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bilirubin (total): Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine: Grade 1 | 3 | 1 | 2 | 8 | 16 | 2 |
| Creatinine: Grade 2 | 0 | 1 | 1 | 0 | 3 | 2 |
| Creatinine: Grade 3 | 0 | 0 | 0 | 0 | 0 | 1 |
| Creatinine: Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia: Grade 1 | 0 | 0 | 0 | 0 | 2 | 1 |
| Hypercalcemia: Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia: Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia: Grade 1 | 2 | 1 | 3 | 4 | 13 | 3 |
| Hyperglycemia: Grade 2 | 0 | 0 | 0 | 4 | 5 | 1 |
| Hyperglycemia: Grade 3 | 0 | 1 | 0 | 0 | 1 | 0 |
| Hyperglycemia: Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia: Grade 1 | 0 | 0 | 1 | 1 | 5 | 0 |
| Hyperkalemia: Grade 2 | 0 | 0 | 0 | 0 | 1 | 0 |
| Hyperkalemia: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia: Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia: Grade 1 | 0 | 0 | 1 | 1 | 3 | 1 |
| Hypermagnesemia: Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia: Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia: Grade 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Hypernatremia: Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia: Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia: Grade 1 | 2 | 2 | 0 | 1 | 3 | 0 |
| Hypoalbuminemia: Grade 2 | 0 | 0 | 1 | 3 | 6 | 4 |
| Hypoalbuminemia: Grade 3 | 0 | 0 | 0 | 0 | 2 | 0 |
| Hypoalbuminemia: Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia: Grade 1 | 0 | 0 | 1 | 1 | 9 | 2 |
| Hypocalcemia: Grade 2 | 0 | 0 | 0 | 0 | 2 | 1 |
| Hypocalcemia: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia: Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia: Grade 1 | 0 | 0 | 0 | 0 | 4 | 0 |
| Hypoglycemia: Grade 2 | 0 | 0 | 0 | 0 | 2 | 0 |
| Hypoglycemia: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia: Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia: Grade 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Hypokalemia: Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia: Grade 3 | 0 | 0 | 2 | 0 | 0 | 0 |
| Hypokalemia: Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia: Grade 1 | 0 | 0 | 2 | 0 | 2 | 1 |
| Hypomagnesemia: Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypomagnesemia: Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia: Grade 1 | 0 | 1 | 0 | 2 | 5 | 1 |
| Hyponatremia: Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia: Grade 3 | 0 | 0 | 0 | 1 | 0 | 0 |
| Hyponatremia: Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypophosphatemia: Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypophosphatemia: Grade 2 | 0 | 1 | 1 | 4 | 6 | 3 |
| Hypophosphatemia: Grade 3 | 0 | 0 | 0 | 1 | 5 | 1 |
| Hypophosphatemia: Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gamma glutamyl transferase : Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gamma glutamyl transferase : Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gamma glutamyl transferase : Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gamma glutamyl transferase : Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| millimeters of mercury (mmHg) | Dose Escalation Part: Crizotinib 200mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 250mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 200 mg+Axitinib 5 mg | Dose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg |
|---|---|---|---|---|---|---|
| SBP: At Baseline | 115.7 ± 13.66 | 116.2 ± 4.91 | 124.8 ± 9.17 | 113.6 ± 12.16 | 131.4 ± 15.58 | 139.7 ± 14.41 |
| SBP: Change at Cycle 1 Day 1 | 2.0 ± 7.25 | 17.3 ± 2.25 | 14.5 ± 14.76 | 15.5 ± 14.92 | -1.7 ± 19.34 | — |
| SBP: Change at Cycle 1 Day 15 | 6.8 ± 9.00 | 3.5 ± 10.04 | 8.7 ± 9.45 | 12.0 ± 18.21 | 4.2 ± 17.06 | -1.9 ± 9.47 |
| SBP: Change at Cycle 2 Day 1 | 0.7 ± 8.13 | 4.3 ± 3.33 | 0.7 ± 9.81 | 0.9 ± 7.47 | -1.8 ± 10.40 | -11.5 ± 20.04 |
| SBP: Change at Cycle 4 Day 1 | — | 3.5 | -5.8 ± 8.01 | 2.3 ± 17.01 | -0.4 ± 12.75 | -14.2 ± 7.54 |
| SBP: Change at Cycle 6 Day 1 | — | -15.0 | 9.8 ± 19.45 | 1.5 ± 15.90 | 0.3 ± 18.57 | -10.4 ± 17.50 |
| SBP: Change at Cycle 12 Day 1 | — | -7.5 | -7.0 | -7.3 ± 1.77 | -5.8 ± 14.54 | -14.0 ± 2.83 |
| SBP: Change at Cycle 24 Day 1 | — | — | 7.0 | 9.0 | -9.0 | — |
| SBP: End of Treatment | -7.0 ± 13.44 | -4.8 ± 10.25 | -14.0 ± 17.58 | 4.9 ± 9.32 | -0.7 ± 15.17 | -12.4 ± 22.00 |
| DBP: At Baseline | 76.8 ± 11.99 | 83.0 ± 4.77 | 83.5 ± 3.03 | 75.8 ± 7.66 | 78.5 ± 10.59 | 76.7 ± 10.37 |
| DBP: Change at Cycle 1 Day 1 | 2.1 ± 4.57 | 4.2 ± 7.77 | 4.8 ± 5.30 | 7.0 ± 11.23 | 5.3 ± 8.84 | — |
| DBP: Change at Cycle 1 Day 15 | 0.7 ± 12.34 | -2.2 ± 1.04 | 2.5 ± 11.65 | 3.9 ± 8.51 | 1.8 ± 10.43 | -7.5 ± 10.54 |
| DBP: Change at Cycle 2 Day 1 | -2.8 ± 7.09 | -2.3 ± 2.57 | 0.5 ± 3.12 | -2.3 ± 5.61 | 0.5 ± 8.36 | -2.4 ± 6.01 |
| DBP: Change at Cycle 4 Day 1 | — | 3.0 | -4.8 ± 2.02 | -2.6 ± 7.94 | -1.0 ± 10.24 | -4.7 ± 4.89 |
| DBP: Change at Cycle 6 Day 1 | — | -17.5 | -0.5 ± 14.14 | -6.0 ± 4.92 | -3.0 ± 13.62 | -1.4 ± 12.96 |
| DBP: Change at Cycle 12 Day 1 | — | -7.0 | 2.5 | -7.5 ± 7.07 | -0.3 ± 11.25 | -5.5 ± 1.41 |
| DBP: Change at Cycle 24 Day 1 | — | — | -1.0 | 7.0 | -6.5 | — |
| DBP: End of Treatment | -1.5 ± 4.44 | -4.5 ± 4.24 | -6.2 ± 8.13 | -2.3 ± 9.58 | -2.8 ± 10.94 | -4.8 ± 11.17 |
| beats per minute (bpm) | Dose Escalation Part: Crizotinib 200mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 250mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 200 mg+Axitinib 5 mg | Dose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg |
|---|---|---|---|---|---|---|
| Pulse Rate: At Baseline | 88.4 ± 21.76 | 81.2 ± 4.25 | 82.6 ± 15.05 | 80.9 ± 7.70 | 73.9 ± 14.71 | 77.4 ± 11.66 |
| Pulse Rate: Change at Cycle 1 Day 1 | -0.6 ± 9.44 | 5.3 ± 9.29 | -7.8 ± 1.44 | -0.3 ± 9.15 | -0.0 ± 12.25 | — |
| Pulse Rate: Change at Cycle 1 Day 15 | -16.0 ± 7.26 | -12.7 ± 6.33 | -7.7 ± 26.63 | -8.1 ± 9.20 | -3.8 ± 11.55 | -14.1 ± 11.93 |
| Pulse Rate: Change at Cycle 2 Day 1 | -10.8 ± 15.25 | -1.5 ± 6.14 | -8.2 ± 23.91 | -0.4 ± 12.09 | -7.5 ± 11.39 | -15.3 ± 13.26 |
| Pulse Rate: Change at Cycle 4 Day 1 | — | -4.0 | -9.7 ± 4.54 | -3.7 ± 8.45 | -0.4 ± 16.15 | -11.1 ± 7.97 |
| Pulse Rate: Change at Cycle 6 Day 1 | — | -7.0 | -7.5 ± 7.78 | -8.5 ± 13.31 | -4.7 ± 18.60 | -3.1 ± 23.69 |
| Pulse Rate: Change at Cycle 12 Day 1 | — | 1.0 | 10.0 | -4.8 ± 6.72 | -2.8 ± 9.75 | -2.5 ± 7.78 |
| Pulse Rate: Change at Cycle 24 Day 1 | — | — | -11.0 | -20.5 | 2.0 | — |
| Pulse Rate: Change at End of Treatment | -19.3 ± 11.59 | 8.0 ± 12.73 | -2.8 ± 12.89 | -1.2 ± 11.55 | 5.4 ± 20.42 | 17.6 ± 18.80 |
| kilograms | Dose Escalation Part: Crizotinib 200mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 250mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 200 mg+Axitinib 5 mg | Dose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg |
|---|---|---|---|---|---|---|
| Body Weight: At Baseline | 74.96 ± 11.339 | 87.43 ± 9.684 | 78.46 ± 13.938 | 82.63 ± 18.346 | 86.54 ± 17.044 | 93.00 ± 17.820 |
| Body Weight: Change at Cycle 1 Day 1 | -1.03 ± 0.379 | -1.43 ± 0.751 | -1.51 ± 1.917 | -0.98 ± 0.829 | -0.63 ± 2.227 | — |
| Body Weight: Cycle 1 Day 15 | -1.17 ± 1.747 | -3.87 ± 2.003 | -2.40 ± 3.064 | -1.56 ± 1.565 | -1.16 ± 2.305 | -1.72 ± 1.648 |
| Body Weight: Change at Cycle 2 Day 1 | -2.08 ± 3.123 | -6.27 ± 2.403 | -3.92 ± 3.806 | -2.28 ± 2.689 | -2.04 ± 3.109 | -1.21 ± 3.734 |
| Body Weight: Change at Cycle 4 Day 1 | — | -2.60 | -5.77 ± 5.228 | -3.36 ± 2.783 | -4.22 ± 4.118 | -2.80 ± 3.609 |
| Body Weight: Change at Cycle 6 Day 1 | — | -3.63 | -14.06 | -3.82 ± 5.538 | -4.18 ± 5.232 | -4.57 ± 6.264 |
| Body Weight: Change at Cycle 12 Day 1 | — | -4.20 | -11.40 | 2.11 ± 2.786 | -3.53 ± 4.366 | -6.15 ± 5.162 |
| Body Weight: Change at Cycle 24 Day 1 | — | — | -16.50 | 8.16 | -2.40 | — |
| Body Weight: Change at End of Treatment | -2.17 ± 5.327 | -6.45 ± 6.576 | -13.60 ± 7.400 | -2.05 ± 7.134 | -5.46 ± 5.505 | -10.68 ± 9.058 |
ECOG-PS: used to assess how disease affected the daily living abilities of participant. It ranges on the scale from: 0-5 (0=fully active/able to carry on all pre-disease activities without restriction;1=restricted in physically strenuous activity but ambulatory/able to carry out light/sedentary work;2=ambulatory \[for more than (\>)50%of waking hours\], capable of all self-care but unable to carry out any work activities;3=capable of limited self-care, confined to bed or chair \[for \>50% of waking hours\];4=completely disabled, not capable of any self-care, totally confined to bed or chair;5= dead, higher score=more functional impairment) and changes to worst status scores were presented. Baseline value=value collected prior to first dose of study drug on Cycle 1 Day 1. Worst post-baseline value=worst value between first dose of any study drug and end of treatment (EOT) visit. Shift to low refers to lower than Baseline value; shift to high refers to higher than baseline value for ECOG-PS.
| Participants | Dose Escalation Part: Crizotinib 200mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 250mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 200 mg+Axitinib 5 mg | Dose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg |
|---|---|---|---|---|---|---|
| Baseline 0, EOT 0 | 0 | 0 | 0 | 0 | 3 | 1 |
| Baseline 0, EOT 1 | 1 | 1 | 2 | 1 | 8 | 0 |
| Baseline 0, EOT 2 | 0 | 0 | 0 | 2 | 0 | 0 |
| Baseline 0, EOT 3 | 0 | 0 | 0 | 1 | 0 | 0 |
| Baseline 0, EOT 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline 1, EOT 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline 1, EOT 1 | 3 | 1 | 0 | 6 | 7 | 2 |
| Baseline 1, EOT 2 | 1 | 0 | 1 | 0 | 2 | 2 |
| Baseline 1, EOT 3 | 0 | 1 | 0 | 0 | 1 | 0 |
| Baseline 1, EOT 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline 2, EOT 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline 2, EOT 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline 2, EOT 2 | 0 | 0 | 0 | 0 | 0 | 1 |
| Baseline 2, EOT 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline 2, EOT 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline 3, EOT 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline 3, EOT 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline 3, EOT 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline 3, EOT 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline 3, EOT 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline 4, EOT 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline 4, EOT 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline 4, EOT 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline 4, EOT 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline 4, EOT 4 | 0 | 0 | 0 | 0 | 0 | 0 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Number of participants with maximum increase from baseline of less than (\<) 30 milliseconds (msec), 30 to \<60 msec and greater than or equal to (\>=) 60 msec were reported.
| Participants | Dose Escalation Part: Crizotinib 200mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 250mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 200 mg+Axitinib 5 mg | Dose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg |
|---|---|---|---|---|---|---|
| QTcF (msec): <30 | 2 | 1 | 2 | 8 | 16 | 4 |
| QTcF (msec): 30-60 | 2 | 2 | 0 | 1 | 4 | 2 |
| QTcF (msec): >=60 | 0 | 0 | 0 | 1 | 0 | 0 |
| QTcB (msec): <30 | 3 | 1 | 1 | 8 | 15 | 4 |
| QTcB (msec): 30 - 60 | 1 | 2 | 1 | 1 | 5 | 2 |
| QTcB (msec): >=60 | 0 | 0 | 0 | 1 | 0 | 0 |
Data of this outcome measure was not planned to be analyzed for Cohort 2 in dose expansion part, as pre-specified in protocol.
| nanogram per milliliter | Dose Escalation Part: Crizotinib 200mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 250mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 200 mg+Axitinib 5 mg | Dose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg |
|---|---|---|---|---|---|
| Axitinib: Lead-in Day 7 | 8.777 ± 34 | 21.33 ± 12 | 31.31 ± 31 | 25.32 ± 101 | 40.21 ± 34 |
| Axitinib: Cycle 1 Day 15 | 6.532 ± 55 | 24.28 ± 115 | 30.89 ± 33 | 25.02 ± 77 | 40.91 ± 55 |
| Crizotinib: Cycle 1 Day 15 | 194.8 ± 6 | 230.8 ± 35 | 169.9 ± 298 | 207.0 ± 43 | 235.9 ± 99 |
Data of this outcome measure was not planned to be analyzed for Cohort 2 in dose expansion part, as pre-specified in protocol.
| hours | Dose Escalation Part: Crizotinib 200mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 250mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 200 mg+Axitinib 5 mg | Dose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg |
|---|---|---|---|---|---|
| Axitinib: Lead-in Day 7 | 2.09 (2.03 to 2.15) | 2.00 (1.03 to 2.00) | 2.48 (1.95 to 3.00) | 3.49 (1.00 to 4.00) | 2.00 (1.00 to 3.98) |
| Axitinib: Cycle 1 Day 15 | 1.50 (1.00 to 2.00) | 3.00 (3.00 to 6.00) | 1.50 (1.00 to 2.00) | 1.50 (1.00 to 2.00) | 2.00 (1.00 to 3.00) |
| Crizotinib: Cycle 1 Day 15 | 12.00 (12.00 to 12.00) | 3.92 (3.07 to 6.00) | 7.00 (2.00 to 12.00) | 3.00 (1.00 to 8.00) | 3.22 (1.00 to 8.08) |
Area under the plasma concentration versus time-curve from time zero to end of dosing interval (AUCtau), where dosing interval was 12 hours. Data of this outcome measure was not planned to be analyzed for Cohort 2 in dose expansion part, as pre-specified in protocol.
| nanogram*hour per milliliter | Dose Escalation Part: Crizotinib 200mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 250mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 200 mg+Axitinib 5 mg | Dose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg |
|---|---|---|---|---|---|
| Axitinib: Lead-in Day 7 | 31.96 ± 61 | 105.9 ± 29 | 131.6 ± 149 | 93.22 ± 135 | 197.8 ± 46 |
| Axitinib: Cycle 1 Day 15 | 34.87 ± 65 | 143.8 ± 107 | 196.8 ± 6 | 127.4 ± 121 | 208.6 ± 35 |
| Crizotinib: Cycle 1 Day 15 | 1905 ± 10 | 2162 ± 33 | 1526 ± 316 | 1985 ± 41 | 2144 ± 105 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent oral clearance was obtained by dividing study drug dose with AUCtau, where AUCtau was area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval. Data of this outcome measure was not planned to be analyzed for Cohort 2 in dose expansion part, as pre-specified in protocol.
| liters per hour | Dose Escalation Part: Crizotinib 200mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 250mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 200 mg+Axitinib 5 mg | Dose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg |
|---|---|---|---|---|---|
| Axitinib: Lead-in Day 7 | 94.06 ± 61 | 28.32 ± 29 | 38.03 ± 149 | 53.70 ± 134 | 25.32 ± 46 |
| Axitinib: Cycle 1 Day 15 | 86.03 ± 65 | 20.86 ± 107 | 25.38 ± 6 | 39.28 ± 121 | 23.96 ± 35 |
| Crizotinib: Cycle 1 Day 15 | 105.0 ± 10 | 115.7 ± 33 | 131.2 ± 316 | 126.0 ± 41 | 116.6 ± 105 |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
No measurements were reported for this outcome.
Percentage of participants with objective response based on assessment of confirmed complete response \[CR\] or confirmed partial response \[PR\] according to Response Evaluation Criteria In Solid Tumors \[RECIST\] version1.1 were reported. Confirmed responses were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.
| percentage of participants | Dose Escalation Part: Crizotinib 200mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 250mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 200 mg+Axitinib 5 mg | Dose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants With Objective Response | 0 (0.0 to 60.2) | 0 (0.0 to 70.8) | 0 (0.0 to 70.8) | 0 (0.0 to 33.6) | 40.0 (19.1 to 63.9) | 14.3 (0.4 to 57.9) |
Duration of response (as per Response Evaluation Criteria in Solid Tumors \[RECIST\] version 1.1) was defined as the time (in months) from first documentation of objective tumor response (complete response \[CR\] or partial response \[PR\]) until the first date that recurrent, progressive disease, or death (whichever occurred first). CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent. Progression was defined as \>= 20 percent increase in sum of longest diameter of target lesions; measurable increase in non-target lesion; appearance of new lesions.
| months | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg |
|---|---|---|
| Dose Expansion Part: Duration of Response | 9.7 (3.6 to 28.6) | NA (NA to NA) |
PFS (as per Response Evaluation Criteria in Solid Tumors \[RECIST\] version 1.1) was defined as the time (in months) from start of study treatment to first documentation of objective tumor progression or death due to any cause, whichever occurred first. PFS (in months) was calculated as (first event date minus date of first dose of study medication plus 1) divided by 30.44. Progression was defined as \>= 20 percent increase in sum of longest diameter of target lesions; measurable increase in non-target lesion; appearance of new lesions. PFS was not estimated in Dose Expansion Cohort 2 due to small sample size.
| months | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg |
|---|---|---|
| Dose Expansion Part: Progression-Free Survival (PFS) | 5.6 (3.5 to 13.6) | NA (NA to NA) |
Serum soluble protein biomarkers included angiopoietin-2, Hepatocyte Growth Factor (HGF), Vascular Endothelial Growth Factor Receptor 3 (VEGFR 3). Biomarker analysis was not planned to be performed in dose escalation part and Cohort 2 of dose expansion part, as pre-specified in protocol.
| nanograms per milliliter (ng/mL) | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg |
|---|---|
| Angiopoietin-2: Baseline | 4.84 ± 5.282 |
| Angiopoietin-2: Cycle 2 Day 1 | 3.81 ± 2.351 |
| Angiopoietin-2: End of Treatment | 5.44 ± 2.996 |
| HGF: Baseline | 9.59 ± 4.831 |
| HGF: Cycle 2 Day 1 | 15.58 ± 22.897 |
| HGF: End of Treatment | 11.95 ± 5.237 |
| VEGFR3: Baseline | 35.368 ± 8.6166 |
| VEGFR3: Cycle 2 Day 1 | 26.000 ± 8.3314 |
| VEGFR3: End of Treatment | 36.444 ± 20.2426 |
No measurements were reported for this outcome.
Percentage of c-MET positive tumor cell for objective response (complete response \[CR\] + partial response \[PR\]) is reported. Objective response was defined as CR and PR. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent. Biomarker analysis was not planned to be performed in dose escalation part and Cohort 2 of dose expansion part, as pre-specified in protocol.
| percentage of positive tumor cells | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg |
|---|---|
| Percent positive cell c-MET Cytoplasmic: CR +PR | 70.0 ± 25.50 |
| Percent positive cell c-MET Membrane: CR + PR | 85.0 ± 20.62 |
Plasma soluble protein biomarker included c-MET. Biomarker analysis was not planned to be performed in dose escalation part and Cohort 2 of dose expansion part, as pre-specified in protocol.
| nanogram per milliliter (ng/mL) | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg |
|---|---|
| c-MET: Baseline | 640.0 ± 120.77 |
| c-MET: Cycle 1 Day 1 | 667.4 ± 117.09 |
| c-MET: Cycle 1 Day 15 | 694.8 ± 143.41 |
| c-MET: Cycle 2 Day 1 | 757.1 ± 148.75 |
| c-MET: Cycle 3 Day 1 | 678.2 ± 120.46 |
| c-MET: Cycle 5 Day 1 | 689.8 ± 158.09 |
| c-MET: End of Treatment | 759.0 ± 183.74 |
Serum soluble protein biomarkers included angiopoietin-2, Hepatocyte Growth Factor (HGF), Vascular Endothelial Growth Factor Receptor 3 (VEGFR3). Ratio=value of serum soluble protein biomarkers at each time point to the value at baseline. Biomarker analysis was not planned to be performed in dose escalation part and Cohort 2 of dose expansion part, as pre-specified in protocol.
| ratio | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg |
|---|---|
| Angiopoietin-2- (Cycle 2 Day 1 ratio Baseline) | 0.90 ± 0.321 |
| Angiopoietin-2 (End of Treatment ratio Baseline) | 1.50 ± 1.056 |
| HGF (Cycle 2 Day 1 ratio Baseline) | 1.62 ± 1.449 |
| HGF (End of Treatment ratio Baseline) | 1.18 ± 0.278 |
| VEGFR3 (Cycle 2 Day 1 ratio Baseline) | 0.748 ± 0.1869 |
| VEGFR3 (End of Treatment ratio Baseline) | 0.969 ± 0.6246 |
Collected over Baseline up to end of treatment (up to 35 cycles in Part 1 and 35 cycles in Part 2, each cycle 28 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Escalation Part: Crizotinib 200mg+Axitinib 3mg | 0/5 (0%) | 2/5 (40%) | 5/5 (100%) |
| Dose Escalation Part: Crizotinib 250mg+Axitinib 3mg | 1/3 (33.3%) | 2/3 (66.7%) | 3/3 (100%) |
| Dose Escalation Part: Crizotinib 200 mg+Axitinib 5 mg | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Dose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg | 0/10 (0%) | 5/10 (50%) | 10/10 (100%) |
| Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg | 2/21 (9.5%) | 8/21 (38.1%) | 21/21 (100%) |
| Dose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg | 1/7 (14.3%) | 3/7 (42.9%) | 7/7 (100%) |
| Event | Dose Escalation Part: Crizotinib 200mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 250mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 200 mg+Axitinib 5 mg | Dose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg |
|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/5 | 1/3 | 0/4 | 0/10 | 0/21 | 0/7 |
| VomitingGastrointestinal disorders | 0/5 | 1/3 | 0/4 | 0/10 | 0/21 | 0/7 |
| Disease progressionGeneral disorders | 0/5 | 1/3 | 0/4 | 0/10 | 2/21 | 0/7 |
| Deep vein thrombosisVascular disorders | 0/5 | 1/3 | 0/4 | 0/10 | 0/21 | 0/7 |
| Acute kidney injuryRenal and urinary disorders | 0/5 | 0/3 | 0/4 | 1/10 | 0/21 | 2/7 |
| DiarrhoeaGastrointestinal disorders | 1/5 | 0/3 | 0/4 | 0/10 | 0/21 | 1/7 |
| Urinary tract infectionInfections and infestations | 1/5 | 0/3 | 0/4 | 0/10 | 0/21 | 0/7 |
| EmbolismVascular disorders | 0/5 | 0/3 | 0/4 | 2/10 | 1/21 | 0/7 |
| Non-cardiac chest painGeneral disorders | 0/5 | 0/3 | 0/4 | 0/10 | 0/21 | 1/7 |
| SepsisInfections and infestations | 0/5 | 0/3 | 0/4 | 0/10 | 0/21 | 1/7 |
| Event | Dose Escalation Part: Crizotinib 200mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 250mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 200 mg+Axitinib 5 mg | Dose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg |
|---|---|---|---|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 2/5 | 3/3 | 3/4 | 5/10 | 7/21 | 1/7 |
| NauseaGastrointestinal disorders | 2/5 | 0/3 | 2/4 | 7/10 | 19/21 | 2/7 |
| VomitingGastrointestinal disorders | 4/5 | 1/3 | 2/4 | 5/10 | 12/21 | 1/7 |
| DiarrhoeaGastrointestinal disorders | 3/5 | 0/3 | 3/4 | 6/10 | 16/21 | 4/7 |
| FatigueGeneral disorders | 1/5 | 2/3 | 3/4 | 7/10 | 9/21 | 5/7 |
| HypothyroidismEndocrine disorders | 2/5 | 2/3 | 2/4 | 1/10 | 3/21 | 0/7 |
| Abdominal painGastrointestinal disorders | 0/5 | 2/3 | 0/4 | 0/10 | 3/21 | 1/7 |
| ConstipationGastrointestinal disorders | 1/5 | 2/3 | 2/4 | 2/10 | 3/21 | 3/7 |
| ProteinuriaRenal and urinary disorders | 3/5 | 2/3 | 0/4 | 3/10 | 5/21 | 0/7 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 0/5 | 2/3 | 1/4 | 4/10 | 11/21 | 2/7 |
Safety analysis population included all enrolled participants who received at least 1 dose of axitinib or crizotinib.
| Age, Continuous(years) | Dose Escalation Part: Crizotinib 200mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 250mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 200 mg+Axitinib 5 mg | Dose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 63.2 ± 2.2 | 48.7 ± 14.5 | 60.3 ± 6.2 | 63.9 ± 6.0 | 62.4 ± 7.9 | 61.9 ± 8.9 | 61.7 ± 8.1 |
| Sex: Female, Male(Participants) | Dose Escalation Part: Crizotinib 200mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 250mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 200 mg+Axitinib 5 mg | Dose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg | Total |
|---|---|---|---|---|---|---|---|
| Female | 1 | 1 | 3 | 5 | 6 | 0 | 16 |
| Male | 4 | 2 | 1 | 5 | 15 | 7 | 34 |
| Race/Ethnicity, Customized(Participants) | Dose Escalation Part: Crizotinib 200mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 250mg+Axitinib 3mg | Dose Escalation Part: Crizotinib 200 mg+Axitinib 5 mg | Dose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg | Dose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg | Total |
|---|---|---|---|---|---|---|---|
| White | 5 | 3 | 2 | 10 | 21 | 5 | 46 |
| Black | 0 | 0 | 1 | 0 | 0 | 1 | 2 |
| Asian | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Other | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Feb 2014 to primary completion in Feb 2017, 35 months.
Results were first posted in Jun 2019, 2 years 3 months after primary completion.
Of 41 industry-sponsored phase 1 interventional studies under Carcinoma, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 68. This study's 35 months is close to that.
Counting every sponsor, half of 70 studies reached it within 46 months; a quarter within 30 and three quarters within 92.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Axitinib · Crizotinib